Netherlands Pharmacogenetic Testing Market to 2032
Overview
The Netherlands Pharmacogenetic Testing Market is expected to reach a 179.72 USD Million by 2032 and is projected to grow at a CAGR of 9.12% from 2025 to 2032.
Netherlands Pharmacogenetic Testing Market 2018-2032 USD Million
Netherlands Pharmacogenetic Testing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 108.05 USD Million
- Projected Market Size (2032): 179.72 USD Million
- CAGR (2025-2032): 9.12%
Key Findings of Netherlands Pharmacogenetic Testing Market
- The Netherlands Pharmacogenetic Testing Market was valued at 108.05 USD Million in 2024.
- The Netherlands Pharmacogenetic Testing Market is likely to grow at a CAGR of 9.12% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Blood in Sample Segment accounted for the largest share of the market with a revenue of 59.35 USD Million
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 13.50% during the forecast period from 2024 to 2032.
Netherlands Pharmacogenetic Testing Market Scope
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
- Drug Regulation
- Drug Development
- Clinical Practice
- Saliva
- Blood
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Netherlands Pharmacogenetic Testing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 108.05 USD Million |
| Market Value in 2032 | 179.72 USD Million |
| CAGR (2025-2032) | 9.12% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Therapeutic Area,Application,Sample,Drug,Distribution Channel,End User,Type,Gene |
Regional Insights:
-
Leading Market (2024-2032): Netherlands, leading in terms of revenue 108.05 USD Million in 2024
- Key Country: Netherlands, leading in terms of revenue with value of 108.05 USD Million in 2024.
Segments and Scope
-
Netherlands Pharmacogenetic Testing Market to 2032, By Therapeutic Area
- Cardiology is the largest segment in Netherlands Pharmacogenetic Testing Market to 2032 with a revenue of 20.06 USD Million in the year 2024.
- Cardiology is the Fastest growing segment in Netherlands Pharmacogenetic Testing Market to 2032 with a Growth rate of 12.84 % in forecast period 2025-2032.
-
Netherlands Pharmacogenetic Testing Market to 2032, By Application
- Clinical Practice is the largest segment in Netherlands Pharmacogenetic Testing Market to 2032 with a revenue of 49.07 USD Million in the year 2024.
- Clinical Practice is the Fastest growing segment in Netherlands Pharmacogenetic Testing Market to 2032 with a Growth rate of 9.64 % in forecast period 2025-2032.
-
Netherlands Pharmacogenetic Testing Market to 2032, By Sample
- Blood is the largest segment in Netherlands Pharmacogenetic Testing Market to 2032 with a revenue of 59.35 USD Million in the year 2024.
- Blood is the Fastest growing segment in Netherlands Pharmacogenetic Testing Market to 2032 with a Growth rate of 9.31 % in forecast period 2025-2032.
-
Netherlands Pharmacogenetic Testing Market to 2032, By Drug
- Prescription Drugs is the largest segment in Netherlands Pharmacogenetic Testing Market to 2032 with a revenue of 34.04 USD Million in the year 2024.
- Prescription Drugs is the Fastest growing segment in Netherlands Pharmacogenetic Testing Market to 2032 with a Growth rate of 10.38 % in forecast period 2025-2032.
-
Netherlands Pharmacogenetic Testing Market to 2032, By Distribution Channel
- Hospital Pharmacy is the largest segment in Netherlands Pharmacogenetic Testing Market to 2032 with a revenue of 49.21 USD Million in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in Netherlands Pharmacogenetic Testing Market to 2032 with a Growth rate of 9.72 % in forecast period 2025-2032.
-
Netherlands Pharmacogenetic Testing Market to 2032, By End User
- Healthcare Providers is the largest segment in Netherlands Pharmacogenetic Testing Market to 2032 with a revenue of 43.88 USD Million in the year 2024.
- Healthcare Providers is the Fastest growing segment in Netherlands Pharmacogenetic Testing Market to 2032 with a Growth rate of 9.88 % in forecast period 2025-2032.
-
Netherlands Pharmacogenetic Testing Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in Netherlands Pharmacogenetic Testing Market to 2032 with a revenue of 51.97 USD Million in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in Netherlands Pharmacogenetic Testing Market to 2032 with a Growth rate of 9.70 % in forecast period 2025-2032.
-
Netherlands Pharmacogenetic Testing Market to 2032, By Gene
- CYP2C19 is the largest segment in Netherlands Pharmacogenetic Testing Market to 2032 with a revenue of 15.97 USD Million in the year 2024.
- CYP2C19 is the Fastest growing segment in Netherlands Pharmacogenetic Testing Market to 2032 with a Growth rate of 13.50 % in forecast period 2025-2032.
Netherlands Pharmacogenetic Testing Market Company Share Analysis
| Company Name |
|
||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| QIAGEN | |||
| Sonic Healthcare Limited | |||
| BGI | |||
Netherlands Pharmacogenetic Testing Market Geographical Sales Distribution, 2018-2032 USD Million
Netherlands Pharmacogenetic Testing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
Netherlands Pharmacogenetic Testing Market Scope
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
- Drug Regulation
- Drug Development
- Clinical Practice
- Saliva
- Blood
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Frequently Asked Questions
Netherlands Pharmacogenetic Testing Market Company Profiling
Frequently Asked Questions
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.